Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERTIGO: Perioperative Empagliflozin to Prevent Cardiac Surgery-Associated AKI
2024-519997-37-00Phase 3Authorised
- Sponsor
- Hospital Clínico Universitario de Valladolid
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) comparing Empagliflozin (Jardiance) with Placebo (microcrystalline cellulose) (2 arms). Primary endpoint: Composite endpoint of renal function worsening, renal replacement therapy, or death. Planned start Jan 2025; status: authorised.
02
Drugs
empagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2024-519997-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519997-37-00.